Benzinga | Oct 8, 2021 08:46AM EDT

Barclays Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $68

Barclays analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Equal-Weight and lowers the price target from $71 to $68.